MISO Chip develops predictive assays that analyze the effectiveness of anticancer therapies, enabling clinicians to customize treatment plans based on empirical data. This technology mitigates the risk of ineffective treatment selection, enhancing patient outcomes and minimizing the trial-and-error approach in cancer care.
Funding
$3.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for assessing the effectiveness of anticancer therapies often rely on trial-and-error, leading to delays in identifying the most suitable treatment and potentially compromising patient outcomes. Traditional preclinical platforms may not accurately represent the complexity of human tumors and their microenvironment, hindering the development of effective therapies.
Solution
MISO Chip offers a patient-derived tumor-on-a-chip platform that enables ex vivo testing of anticancer agents on micro-dissected human tumors, preserving their native tumor microenvironment (TME). The microfluidic platform uses undissociated, uniform tumor fragments to capture the heterogeneity of the primary tissue, providing a human-relevant model for drug development. This approach allows biotech and pharmaceutical companies to make informed decisions about lead compounds before entering clinical trials. MISO Chip's technology offers higher throughput and viability compared to standard explant models, facilitating more efficient and predictive drug testing.
Target Audience
The primary customers are biotech and pharmaceutical companies involved in oncology drug development, as well as academic researchers in translational oncology.
Features
- 3D microfluidic devices for culturing micro-dissected tissues (MDT)
- Ex vivo testing of anticancer agents on patient-derived tumor samples
- Preservation of the native tumor microenvironment (TME)
- Undissociated tumor fragments to maintain tissue heterogeneity
- High-throughput screening capabilities, 5-10x greater than standard explant models
- Extended tissue viability of up to 15 days ex vivo without perfusion
- Customizable study design for target engagement, pathway modulation, drug combination testing, and efficacy assays